PET Imaging for Neurodegenerative Diseases

PET Imaging for Neurodegenerative Diseases

Introduction

Positron Emission Tomography (PET) imaging is a powerful molecular imaging technique that enables visualization and quantification of pathological processes in the living brain. PET has become indispensable for diagnosing neurodegenerative diseases, tracking disease progression, and evaluating therapeutic efficacy in clinical trials["@pet2023"][@tau2022].

Principles of PET Imaging

How PET Works

Radioactive tracer: Patient receives positron-emitting radiopharmaceutical

Positron emission: Radioactive decay releases positrons

Annihilation: Positrons collide with electrons, producing gamma rays

Detection: Ring of detectors captures gamma photon pairs

Reconstruction: Tomographic algorithms create 3D images

Key Tracer Properties

• Half-life: Determines imaging window (e.g., F-18: 110 min, C-11: 20 min)
• Specificity: Binding affinity for target of interest
• Blood-brain barrier penetration: Essential for CNS applications
• Signal-to-noise: Clear distinction between target and background

PET Tracers for Neurodegeneration

Amyloid Imaging

...

PET Imaging for Neurodegenerative Diseases

Introduction

Positron Emission Tomography (PET) imaging is a powerful molecular imaging technique that enables visualization and quantification of pathological processes in the living brain. PET has become indispensable for diagnosing neurodegenerative diseases, tracking disease progression, and evaluating therapeutic efficacy in clinical trials["@pet2023"][@tau2022].

Principles of PET Imaging

How PET Works

Radioactive tracer: Patient receives positron-emitting radiopharmaceutical

Positron emission: Radioactive decay releases positrons

Annihilation: Positrons collide with electrons, producing gamma rays

Detection: Ring of detectors captures gamma photon pairs

Reconstruction: Tomographic algorithms create 3D images

Key Tracer Properties

• Half-life: Determines imaging window (e.g., F-18: 110 min, C-11: 20 min)
• Specificity: Binding affinity for target of interest
• Blood-brain barrier penetration: Essential for CNS applications
• Signal-to-noise: Clear distinction between target and background

PET Tracers for Neurodegeneration

Amyloid Imaging

Florbetapir (Amyvid)

• Target: Amyloid-beta plaques
• Binding: Beta-sheet structures
• Status: FDA approved for Alzheimer's diagnosis
• Clinical use: Distinguishing AD from other dementias

Florbetaben

• Target: Amyloid plaques
• Status: Approved in Europe and FDA conditional
• Strengths: High specificity for amyloid

PiB (Pittsburgh Compound B)

• Target: Amyloid plaques
• Research: Widely used in research settings
• Limitations: Short half-life (C-11)

Tau Imaging

Flortaucipir (Tauvid)

• Target: [Neurofibrillary tangles](/mechanisms/tau-pathology) ([tau](/proteins/tau-protein) protein)
• Status: FDA approved for [tau](/proteins/tau-protein) imaging
• Clinical utility: Correlates with clinical staging

MK-6240

• Target: [Tau](/proteins/tau-protein) aggregates
• Properties: High affinity, good kinetics
• Research: Widely used in trials

APN-1607

• Target: Tau pathology
• Development: Clinical trials ongoing

Synaptic Density

Synaptic Vesicle Protein 2A (SV2A) Tracers

• UCB-J (NeuraTrace): SV2A imaging for synaptic density
• Clinical use: Tracking neurodegeneration
• Advantage: Direct measure of neuronal loss

Neuroinflammation

TSPO Tracers

• PK11195: First-generation TSPO ligand
• PBR28: Second-generation with improved binding
• Target: Activated microglia
• Challenge: Genetic variability in binding

Dopaminergic Imaging

F-DOPA

• Target: Dopamine synthesis capacity
• Use: [Parkinson's disease](/diseases/parkinsons-disease) diagnosis
• Clinical: Differentiating [PD](/diseases/parkinsons-disease) from other parkinsonisms

FP-CIT (DaTscan)

• Target: Dopamine transporter
• Status: FDA approved
• Clinical: Differentiating essential tremor from [PD](/diseases/parkinsons-disease)

Raclopride

• Target: D2 dopamine receptors
• Use: Dopamine release studies

Alpha-Synuclein PET Tracers

Alpha-synuclein PET imaging represents one of the most significant unmet needs in neurodegenerative disease diagnostics. Unlike amyloid and tau PET, which have FDA-approved tracers, alpha-synuclein PET has historically lagged behind. At AD/PD 2026 in Copenhagen (March 17-21, 2026), researchers announced that a new generation of alpha-synuclein PET tracers has entered human testing — marking a major milestone for Parkinson's disease and synucleinopathy diagnostics.

Key Developments from AD/PD 2026

• Human testing milestone: Multiple alpha-synuclein PET tracers presented early PET imaging studies in people with different synucleinopathies (Parkinson's disease, Dementia with Lewy Bodies, Multiple System Atrophy)
• Target validation: Tracers designed to bind to alpha-synuclein aggregates in vivo, enabling visualization of Lewy body pathology
• Differentiation potential: Early data suggests tracers may help distinguish between different synucleinopathies based on regional binding patterns

Tracer Development Landscape

| Company/Developer | Tracer | Stage | Notes |
|------------------|--------|-------|-------|
| MODAG | Novel α-syn PET tracer | Phase I | Presented at AD/PD 2026 |
| Various academic groups | Multiple candidates | Phase I/II | Early human imaging studies |
| Industry consortia | Next-gen tracers | Preclinical | Optimizing specificity |

Challenges for Alpha-Synuclein PET

Developing alpha-synuclein PET tracers is particularly challenging because:

• Alpha-synuclein aggregates exist in multiple morphologies (fibrils, oligomers, membranes)
• Non-specific binding to other proteins can confound signal
• Lower abundance compared to amyloid plaques requires higher sensitivity
• Species differences in tracer validation

Clinical Applications (Future)

Once validated, alpha-synuclein PET will enable:

• Differential diagnosis: Distinguishing PD from other parkinsonisms (MSA, PSP)
• DLB confirmation: Visualizing cortical Lewy body burden
• Disease staging: Tracking alpha-synuclein spread through Braak stages in vivo
• Clinical trials: Enrollment criteria and target engagement for alpha-synuclein therapies
• Progression monitoring: Measuring pathological spread over time

Other Targets

Monoamine Oxidase B (MAO-B)

• Target: MAO-B in astrocytes
• Example: PBR111
• Use: Neuroinflammation assessment

5-HT1A Receptors

• Example: WAY-100635
• Use: Serotonergic dysfunction in AD

Advantages

Quantitative: Provides numerical measures of pathology

Molecular specificity: Visualizes specific proteins/processes

Longitudinal tracking: Can monitor disease progression

Clinical trials: Enables biomarker-driven studies

Early detection: Can identify pathology before symptoms

Challenges

Radiopharmaceutical production: Requires cyclotron and chemistry expertise

Cost: Equipment and tracer production expensive

Radiation exposure: Limited repeat imaging

Partial volume effects: Small structures underestimated

Non-specific binding: Background signal can confound results

Biomarker validation: Some tracers lack proven clinical utility

Clinical Applications

Diagnosis

• Differential diagnosis: Distinguishing between [dementia](/diseases/alzheimers-disease) types
• Parkinsonism: Differentiating [PD](/diseases/parkinsons-disease) from [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
• Preclinical detection: Identifying at-risk individuals

Disease Staging

• Amyloid burden: Correlates with disease severity
• [Tau](/proteins/tau-protein) spread: Tracks Braak staging in vivo
• Disease progression: Longitudinal imaging studies

Clinical Trials

• Enrollment criteria: Selecting amyloid-positive patients
• Target engagement: Demonstrating drug binding
• Treatment response: Measuring pathological changes

Current Development Stage

Approved Tracers

• Florbetapir (Amyvid): Amyloid imaging
• Florbetaben: Amyloid imaging
• Flortaucipir (Tauvid): Tau imaging
• F-DOPA: Dopamine imaging
• FP-CIT (DaTscan): Dopamine transporter imaging

Pipeline

| Target | Tracers | Stage |
|--------|---------|-------|
| Tau | Multiple | Phase II/III |
| Synaptic density | UCB-J | Clinical |
| Alpha-synuclein | Multiple | Phase I (human testing) |
| TDP-43 | Early development | Preclinical |

March 2026 update: At AD/PD 2026, researchers announced that a new generation of alpha-synuclein PET tracers has entered human testing, marking a major milestone for synucleinopathy diagnostics.

Companies and Institutions

Radiopharmaceutical Companies

• Avid Radiopharmaceuticals (Eli Lilly): Florbetapir, Flortaucipir
• GE Healthcare: Various tracers
• Siemens: Tracer development
• PerkinElmer: Research tracers

Academic Centers

• Washington University: PET tracer development
• UCLA: Amyloid and tau imaging
• University of Pennsylvania: Neuroinflammation imaging
• Karolinska Institute: Dopamine imaging

Research Initiatives

• Alzheimer's Disease Neuroimaging Initiative (ADNI): PET imaging protocols
• Michael J. Fox Foundation: Parkinson's imaging biomarkers
• Centres for Tau Program: Tau tracer validation

PET/CT and PET/MRI

PET/CT

• Standard: Most common hybrid system
• Advantages: CT provides anatomical reference
• Limitations: Radiation from CT

PET/MRI

• Emerging: Growing clinical adoption
• Advantages: No additional radiation, better soft tissue
• Challenges: More complex operation

Future Directions

Novel Targets

• Alpha-synuclein: Critical for Parkinson's, DLB
• TDP-43: For ALS, FTD
• alpha-Synuclein seeds: Detecting prion-like spread

Technological Advances

• Total-body PET: Faster, lower dose imaging
• Kinetic modeling: Improved quantification
• Artificial intelligence: Image enhancement, analysis

Combination Approaches

• PET/MRI hybrid imaging
• Theranostics: Diagnostic + therapeutic
• Multi-tracer protocols

Comparison with Other Imaging

| Modality | Spatial Resolution | Molecular Info | Cost | Radiation |
|----------|-------------------|----------------|------|-----------|
| PET | 4-5 mm | High | High | High |
| MRI | 1 mm | Medium | Medium | None |
| CT | 1 mm | Low | Medium | Medium |
| SPECT | 8-10 mm | Medium | Low | Medium |

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Biomarkers](/biomarkers)
• [Neuroimaging](/technologies/neuroimaging)
• [Flortaucipir](/biomarkers/flortaucipir)
• [Florbetapir](/biomarkers/florbetapir)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, PET imaging in Alzheimer's disease (Nature Reviews Neurology, 2023) (2023)](https://doi.org/10.1038/s41582-023-00751-0)

[Unknown, Tau PET imaging in neurodegenerative diseases (Molecular Psychiatry, 2022) (2022)](https://doi.org/10.1038/s41380-022-01669-4)

[Unknown, Molecular imaging of neurodegeneration (Lancet Neurology, 2023) (2023)](https://doi.org/10.1016/S1474-4422(23)